EMA and FDA unveil joint AI principles to transform drug revelopment
Experts caution that realizing AI’s potential requires careful management and risk mitigation
Experts caution that realizing AI’s potential requires careful management and risk mitigation
BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company
The partnership will launch a Phase 1b cohort within Boehringer’s ongoing Beamion-BCGC1 trial
Projects selected for advancement will move forward through the Harvard Office of Technology Development’s processes for sponsored research agreements
Iktos will deploy its AI-driven tools to accelerate the identification of optimized small-molecule candidates against a currently undisclosed oncology target
The acquisition of AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) positions Bayer at the forefront of cardiac amyloidosis diagnostics
Subscribe To Our Newsletter & Stay Updated